Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

CytomX Therapeutics Inc

CTMX
Current price
1.67 USD -0.05 USD (-2.91%)
Last closed 1.73 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 145 623 376 USD
Yield for 12 month +2.45 %
1Y
3Y
5Y
10Y
15Y
CTMX
21.11.2021 - 28.11.2021

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. Address: 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

2.9 USD

P/E ratio

Dividend Yield

Current Year

+101 214 000 USD

Last Year

+53 163 000 USD

Current Quarter

+26 607 000 USD

Last Quarter

+26 384 000 USD

Current Year

+99 039 000 USD

Last Year

+53 163 000 USD

Current Quarter

+26 121 000 USD

Last Quarter

+24 958 000 USD

Key Figures CTMX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -4 309 000 USD
Operating Margin TTM -2.28 %
PE Ratio
Return On Assets TTM -1.75 %
PEG Ratio -1.8
Return On Equity TTM -5475.03 %
Wall Street Target Price 2.9 USD
Revenue TTM 101 214 000 USD
Book Value -0.71 USD
Revenue Per Share TTM 1.37 USD
Dividend Share
Quarterly Revenue Growth YOY 32.2 %
Dividend Yield
Gross Profit TTM 53 163 000 USD
Earnings Share -0.01 USD
Diluted Eps TTM -0.01 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin -0.56 %

Dividend Analytics CTMX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CTMX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CTMX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 53.7634
Enterprise Value Revenue 0.0156
Price Sales TTM 1.4388
Enterprise Value EBITDA 3.4606
Price Book MRQ 5.0363

Financials CTMX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CTMX

For 52 weeks

1.04 USD 2.86 USD
50 Day MA 2 USD
Shares Short Prior Month 3 530 600
200 Day MA 1.6 USD
Short Ratio 2.17
Shares Short 3 323 519
Short Percent 4.95 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics